Sterling Bay has recently secured four new biotech tenants at 2430 N. Halsted, a state-of-the-art scientific research facility located in Chicago’s thriving Lincoln Park neighborhood. These new tenants include Seq Biomarque, CeGaT Corporation, EVOQ Therapeutics and Cyclopure.
Seq Biomarque is a leading research and diagnostic technologies company that specializes in developing highly sensitive blood-based multi-factor screening and diagnostic tests for Alzheimer’s disease. CeGaT Corporation is making its debut in the U.S., bringing with them their expertise in genomics and personalized medicine.
EVOQ Therapeutics was founded by researchers from the University of Michigan with the goal of revolutionizing autoimmune disease treatment through innovative immunotherapies. And finally, Cyclopure is an expert in water purification and treatment technologies who will be relocating to this hub from Illinois Science + Technology Park.
The negotiations for these transactions were handled by Dave Gloor and Daniella Hemsley on behalf of Sterling Bay while Jonathan Metzland Jack Deroche represented Cyclopure through Cushman & Wakefield.
Sterling Bay’s life sciences hub offers adaptable lab spaces designed specifically for biotech companies at various stages of growth. With flexible options available to support startups as they scale up their operations, this property provides everything needed for success within the industry.
According to Andy Gloor, CEO of Sterling Bay: “Our focus is on creating a diverse range of spaces that can accommodate our users’ needs throughout every stage of their growth cycle.”
This news was originally published on Connect CRE.
